PharmaCyte Biotech, Inc.
PMCBPharmaCyte Biotech is a clinical-stage biotechnology company focused on developing cellular therapies for cancer using its proprietary Cell-in-a-Box live cell encapsulation technology.
Earnings
Next report
Dec 16, 2026 (in a month)Competitors
Profile
PharmaCyte Biotech is a clinical-stage biotechnology company focused on developing cellular therapies for cancer using its proprietary Cell-in-a-Box live cell encapsulation technology. The company's platform utilizes cellulose-based capsules to protect genetically engineered human cells that convert chemotherapy prodrugs into active cancer-killing agents directly at the tumor site. Its primary development efforts are currently centered on treating locally advanced, inoperable, non-metastatic pancreatic cancer (LAPC).
PharmaCyte is a development-stage entity currently addressing an FDA clinical hold on its lead candidate while leveraging a unique cellulose-based encapsulation technology that offers durability and cryopreservation advantages over traditional alginate-based methods.
FAQ
- What is PharmaCyte Biotech, Inc.'s market cap?
- PharmaCyte Biotech, Inc. (PMCB) has a market capitalization of $3.6M and trades on NASDAQ.
- Who are PharmaCyte Biotech, Inc.'s competitors?
- PharmaCyte Biotech, Inc.'s key competitors include Exicure, Inc. Common Stock, Processa Pharmaceuticals, Inc. Common, CNS Pharmaceuticals, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does PharmaCyte Biotech, Inc. partner with?
- PharmaCyte Biotech, Inc.'s notable partners include SG Austria Pte. Ltd, Austrianova Singapore Pte. Ltd., Bavarian Nordic A/S.
- What subsidiaries does PharmaCyte Biotech, Inc. have?
- PharmaCyte Biotech, Inc.'s subsidiaries include Bio Blue Bird.
- Where is PharmaCyte Biotech, Inc. headquartered?
- PharmaCyte Biotech, Inc. is headquartered in United States of America and employs approximately 2 people. It has been publicly traded since 2003.